NCT01497496 2021-04-27Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)H. Lee Moffitt Cancer Center and Research InstitutePhase 2 Completed29 enrolled 9 charts